Álvarez-Álvarez MM, Zanetti D, Carreras-Torres R, Moral P, Athanasiadis G. A survey of sub-Saharan gene flow into the Mediterranean at risk loci for coronary artery disease. Eur J Hum Genet. 2017;25:472–6. https://doi.org/10.1038/ejhg.2016.200.
Article PubMed PubMed Central Google Scholar
Kumar A. Potential biomarkers to detect inflammation leading to coronary artery disease. J Nat Sci Biol Med. 2020;11:1. https://doi.org/10.4103/0976-9668.280267.
Abid H, Abid Z, Abid S. Atherogenic indices in clinical practice and biomedical research: a short review. Baghdad J Biochem Appl Biol Sci. 2021;2:60–70. https://doi.org/10.47419/bjbabs.v2i02.52.
Patil V, Avhad A, Kulkarni A, Pandere K. High-sensitive C-reactive protein in patients with coronary artery disease. J Nat Sc Biol Med. 2020;11:39. https://doi.org/10.4103/jnsbm.JNSBM_159_19.
Maguire EM, Pearce SWA, Xiao Q. Foam cell formation: a new target for fighting atherosclerosis and cardiovascular disease. Vasc Pharmacol. 2019;112:54–71. https://doi.org/10.1016/j.vph.2018.08.002.
Mittal M, Siddiqui MR, Tran K, Reddy SP, Malik AB. Reactive oxygen species in inflammation and tissue injury. Antioxid Redox Signal. 2014;20:1126–67. https://doi.org/10.1089/ars.2012.5149.
CAS Article PubMed PubMed Central Google Scholar
Ouimet M, Barrett TJ, Fisher EA. HDL and reverse cholesterol transport. Circ Res. 2019;124:1505–18. https://doi.org/10.1161/CIRCRESAHA.119.312617.
CAS Article PubMed PubMed Central Google Scholar
Säemann MD, Poglitsch M, Kopecky C, Haidinger M, Hörl WH, Weichhart T. The versatility of HDL: a crucial anti-inflammatory regulator. Eur J Clin Investig. 2010;40:1131–43. https://doi.org/10.1111/j.1365-2362.2010.02361.x.
Rader DJ, Alexander ET, Weibel GL, Billheimer J, Rothblat GH. The role of reverse cholesterol transport in animals and humans and relationship to atherosclerosis. J Lipid Res. 2009;50(Suppl):S189–94. https://doi.org/10.1194/jlr.R800088-JLR200.
CAS Article PubMed PubMed Central Google Scholar
Fuller J, Jarrett R, Keen H, Pinney S, Avogaro P, Cazzolato G, et al. High-density lipoprotein and atherosclerosis. Lancet. 1975;305:691–2. https://doi.org/10.1016/S0140-6736(75)91801-2.
Gordon T, Castelli WP, Hjortland MC, Kannel WB, Dawber TR. High density lipoprotein as a protective factor against coronary heart disease. The Framingham Study. Am J Med. 1977;62:707–14. https://doi.org/10.1016/0002-9343(77)90874-9.
CAS Article PubMed Google Scholar
Adorni MP, Ronda N, Bernini F, Zimetti F. High density lipoprotein cholesterol efflux capacity and atherosclerosis in cardiovascular disease: pathophysiological aspects and pharmacological perspectives. Cells. 2021. https://doi.org/10.3390/cells10030574.
Hafiane A. Vulnerable plaque, characteristics, detection, and potential therapies. J Cardiovasc Dev Dis. 2019. https://doi.org/10.3390/jcdd6030026.
Nicholls SJ, Puri R, Wolski K, Ballantyne CM, Barter PJ, Brewer HB, et al. Effect of the BET protein inhibitor, RVX-208, on progression of coronary atherosclerosis: results of the phase 2b, randomized, double-blind, multicenter, ASSURE Trial. Am J Cardiovasc Drugs. 2016;16:55–65. https://doi.org/10.1007/s40256-015-0146-z.
CAS Article PubMed Google Scholar
Schwartz GG, Olsson AG, Abt M, Ballantyne CM, Barter PJ, Brumm J, et al. Effects of dalcetrapib in patients with a recent acute coronary syndrome. N Engl J Med. 2012;367:2089–99. https://doi.org/10.1056/NEJMoa1206797.
CAS Article PubMed Google Scholar
Cannon CP, Shah S, Dansky HM, Davidson M, Brinton EA, Gotto AM, et al. Safety of anacetrapib in patients with or at high risk for coronary heart disease. N Engl J Med. 2010;363:2406–15. https://doi.org/10.1056/NEJMoa1009744.
CAS Article PubMed Google Scholar
Barter PJ, Caulfield M, Eriksson M, Grundy SM, Kastelein JJP, Komajda M, et al. Effects of torcetrapib in patients at high risk for coronary events. N Engl J Med. 2007;357:2109–22. https://doi.org/10.1056/NEJMoa0706628.
CAS Article PubMed Google Scholar
Boden WE, Probstfield JL, Anderson T, Chaitman BR, Desvignes-Nickens P, Koprowicz K, et al. Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. N Engl J Med. 2011;365:2255–67. https://doi.org/10.1056/NEJMoa1107579.
CAS Article PubMed Google Scholar
Rothblat GH, La Llera-Moya M, de, Atger V, Kellner-Weibel G, Williams DL, Phillips MC. Cell cholesterol efflux: integration of old and new observations provides new insights. J Lipid Res. 1999;40:781–96.
Niisuke K, Kuklenyik Z, Horvath KV, Gardner MS, Toth CA, Asztalos BF. Composition-function analysis of HDL subpopulations: influence of lipid composition on particle functionality. J Lipid Res. 2020;61:306–15. https://doi.org/10.1194/jlr.RA119000258.
CAS Article PubMed PubMed Central Google Scholar
Khera AV, Cuchel M, La Llera-Moya M, de Rodrigues A, Burke MF, Jafri K, et al. Cholesterol efflux capacity, high-density lipoprotein function, and atherosclerosis. N Engl J Med. 2011;364:127–35. https://doi.org/10.1056/NEJMoa1001689.
CAS Article PubMed PubMed Central Google Scholar
Rohatgi A, Khera A, Berry JD, Givens EG, Ayers CR, Wedin KE, et al. HDL cholesterol efflux capacity and incident cardiovascular events. N Engl J Med. 2014;371:2383–93. https://doi.org/10.1056/NEJMoa1409065.
CAS Article PubMed PubMed Central Google Scholar
Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372:n71. https://doi.org/10.1136/bmj.n71.
Article PubMed PubMed Central Google Scholar
Deeks JJ, Dinnes J, D'Amico R, Sowden AJ, Sakarovitch C, Song F, et al. Evaluating non-randomised intervention studies. Health Technol Assess. 2003;7:iii-x, 1–173. https://doi.org/10.3310/hta7270.
Zhang C, Wang S, Chen S, Yang S, Wan L, Xiong B. Association between pretreatment Glasgow prognostic score and gastric cancer survival and clinicopathological features: a meta-analysis. Onco Targets Ther. 2016;9:3883–91. https://doi.org/10.2147/OTT.S103996.
CAS Article PubMed PubMed Central Google Scholar
Higgins JP. Cochrane handbook for systematic reviews of interventions. Version 5.1. 0: The Cochrane Collaboration; 2011. www.cochrane-handbook.org.
Zhang J, Yu KF. What’s the relative risk? A method of correcting the odds ratio in cohort studies of common outcomes. JAMA. 1998;280:1690–1. https://doi.org/10.1001/jama.280.19.1690.
CAS Article PubMed Google Scholar
Khan AR, Golwala H, Tripathi A, Bin Abdulhak AA, Bavishi C, Riaz H, et al. Impact of total occlusion of culprit artery in acute non-ST elevation myocardial infarction: a systematic review and meta-analysis. Eur Heart J. 2017;38:3082–9. https://doi.org/10.1093/eurheartj/ehx418.
Higgins JPT, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ. 2003;327:557–60. https://doi.org/10.1136/bmj.327.7414.557.
Article PubMed PubMed Central Google Scholar
Xu C, Doi SAR. The robust error meta-regression method for dose-response meta-analysis. Int J Evid Based Healthc. 2018;16:138–44. https://doi.org/10.1097/XEB.0000000000000132.
Agarwala AP, Rodrigues A, Risman M, McCoy M, Trindade K, Qu L, et al. High-density lipoprotein (HDL) phospholipid content and cholesterol efflux capacity are reduced in patients with very high HDL cholesterol and coronary disease. Arterioscler Thromb Vasc Biol. 2015;35:1515–9. https://doi.org/10.1161/ATVBAHA.115.305504.
CAS Article PubMed PubMed Central Google Scholar
Cahill LE, Sacks FM, Rimm EB, Jensen MK. Cholesterol efflux capacity, HDL cholesterol, and risk of coronary heart disease: a nested case-control study in men. J Lipid Res. 2019;60:1457–64. https://doi.org/10.1194/jlr.P093823.
CAS Article PubMed PubMed Central Google Scholar
Ishikawa T, Ayaori M, Uto-Kondo H, Nakajima T, Mutoh M, Ikewaki K. High-density lipoprotein cholesterol efflux capacity as a relevant predictor of atherosclerotic coronary disease. Atherosclerosis. 2015;242:318–22. https://doi.org/10.1016/j.atherosclerosis.2015.06.028.
CAS Article PubMed Google Scholar
Kuusisto S, Holmes MV, Ohukainen P, Kangas AJ, Karsikas M, Tiainen M, et al. Direct estimation of HDL-mediated cholesterol efflux capacity from serum. Clin Chem. 2019;65:1042–50. https://doi.org/10.1373/clinchem.2018.299222.
Li X-M, Tang WHW, Mosior MK, Huang Y, Wu Y, Matter W, et al. Paradoxical association of enhanced cholesterol efflux with increased incident cardiovascular risks. Arterioscler Thromb Vasc Biol. 2013;33:1696–705. https://doi.org/10.1161/ATVBAHA.113.301373.
CAS Article PubMed PubMed Central Google Scholar
Liu C, Zhang Y, Ding D, Li X, Yang Y, Li Q, et al. Cholesterol efflux capacity is an independent predictor of all-cause and cardiovascular mortality in patients with coronary artery disease: a prospective cohort study. Atherosclerosis. 2016;249:116–24. https://doi.org/10.1016/j.atherosclerosis.2015.10.111.
CAS Article PubMed Google Scholar
Luo M, Liu A, Wang S, Wang T, Hu D, Wu S, et al. ApoCIII enrichment in HDL impairs HDL-mediated cholesterol efflux capacity. Sci Rep. 2017;7:2312. https://doi.org/10.1038/s41598-017-02601-7.
CAS Article PubMed PubMed Central Google Scholar
Luo M, Zhang Z, Peng Y, Wang S, Peng D. The negative effect of ANGPTL8 on HDL-mediated cholesterol efflux capacity. Cardiovasc Diabetol. 2018;17:142. https://doi.org/10.1186/s12933-018-0785-x.
留言 (0)